Skip to main content

Intra-Cellular Ther(ITCI-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low131.63
Day High131.98
Open:131.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Tipranks
Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top Analyst
GlobeNewswire
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Wall Street Horizon
Steady M&A Deals to Begin 2025, Disappointing IPOs So Far
MarketBeat
MarketBeat Week in Review – 01/13 - 01/17
MarketBeat
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Barchart
Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus
Trader at NYSE by Orhan Akkurt via Shutterstock
Barchart
Stocks Recover on Strength in Health Insurers and Energy Stocks
Wall street sign in New York with New York Stock Exchange background by Stuart Monk via Shutterstock
Barchart
Stocks Slide and Bond Yields Rise as Fed Rate Cut Hopes Dwindle
Inside NYSE by Orhan Akkurt via Shutterstock
Barchart
Stocks Pressured by Rising Bond Yields as Fed Rate Cut Hopes Fade
Roaring brown bear by Borzywoj via iStock
The Globe and Mail
Market movers: Stocks seeing action on Monday - and why
People sit outside of a Lululemon on November 29, 2024 in New York City
Barchart
Stocks Set to Open Sharply Lower as Fed Rate Cut Hopes Fade, U.S. Inflation Data and Big Bank Earnings in Focus
Wall Street sign in lower Manhattan New York by Stuart Monk via Shutterstock
GlobeNewswire
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz 
GlobeNewswire
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
GlobeNewswire
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
GlobeNewswire
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
GlobeNewswire
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
GlobeNewswire
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
GlobeNewswire
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
GlobeNewswire
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
PressReach
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Motley Fool
Why Intra-Cellular Therapies Climbed Tuesday
BayStreet.ca
With Alzheimer’s Cases Set to Explode in the Near-Term, New Treatments and Diagnostics are Needed
Globe Newswire
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Intra-Cellular Therapies, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Globe Newswire
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm
Motley Fool
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
Motley Fool
Why Intra-Cellular Therapies Trounced the S&P 500 Today
Globe Newswire
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Profile

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.